DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the Human Genetic Resources Administration of China (HGRAC), has approved the Company’s application to initiate a Phase 2 safety and efficacy study of its lead product candidate VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
From Uruguay’s full legalization to the debate between regional leaders in Canada questioning the recreational deadline, and a variety of market news INN provides a roundup of the week in cannabis
By Shelly Kumar
Valens GroWorks (CSE:VGW)(CSE:VGW.CN) (the “Company” or “Valens“) is pleased to announce that Mr. Saul Katz has joined the Company as its President.
Mr. Katz brings to Valens 35 years of entrepreneurship, senior management experience and scientific expertise in functional food product development and commercialization. Over his career he established research collaborations with leading
ESSA Pharma announced it received notification from the NASDAQ Stock Market saying the company doesn’t meet the “minimum bid price requirement” for continued listing.
Thanks to an IND application for RTGel from Allergan, UroGen Pharma will receive a $7.5 million licensing agreement payment.
Data from the P&S Market Research indicated the already lucrative global animal pharmaceutical market, valued at $12,614.3 million total in 2015, will increase at a CAGAR of 7.7 percent by 2022.
Other companies that traded a high volume of shares in Germany last week were Zecotek Photonics, Veritas Pharma, Jaxon Minerals and POET Technologies.
Cardiome Pharma announced it received an approval for AGGRASTAT by Health Canada.
As part of their more critical stance against opioids brought forward by new management, the FDA has requested Endo Pharmaceuticals to remove Opana ER from the market.
ZIVO Bioscience contracted with Algatek, to conduct a pilot program using proprietary Algatek production technology.
M Pharmaceutical gave an update to shareholders on the release of its FDA-cleared products ToConceive in the North American market.
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company developing new cancer therapies, today announced that Mr. Saiid Zarrabian has joined the Company’s Board of Directors and Dr. Erich Mohr has been elected to serve as its Chairman.
This Board strengthening initiative seeks to establish a more robust and independent Board, and
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
By Shelly Kumar
The Green Organic Dutchman Holdings Ltd. (the “Company”) is pleased to announce, following an extensive search, the appointment of Csaba Reider as the Company’s new President and Marc Bertrand as the Company’s new Strategic Advisor.
Mr. Reider is a high-energy senior executive with multinational experience in growing companies through demonstrated